Clinical Trials
6 trialsNCT04045795 2025-09-12
Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Sanofi
Phase 1 Completed
NCT02513186 2024-01-29
Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation
Sanofi
Phase 1 Completed
NCT03733717 2023-09-08
Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma
Sanofi
Phase 1 Completed
NCT01749969 2023-07-13
SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients
Sanofi
Phase 1 Completed
NCT02514668 2022-04-25
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
Sanofi
Phase 1 Completed
NCT02283775 2021-07-09
PomdeSAR
Sanofi
Phase 1 Completed